Protective effect of beta-casomorphin-7 on type 1 diabetes rats induced with streptozotocin.
The present study was aimed to investigate the possible effects of beta-casomorphin-7, against hyperglycemia and free radical-mediated oxidative stress in streptozotocin-induced diabetic rats by assaying the blood glucose level and the activity of plasma enzymatic antioxidants, such as superoxide dismutase (SOD), catalase and glutathione peroxidase (GSH-Px). A significant increase in the levels of both blood glucose and oxidative stress with a predominant decrease in antioxidant status was observed in the diabetic rats when compared to control rats. After 15 days oral administration of beta-casomorphin-7 (7.5 x 10(-8) mol/day), the elevated blood glucose level was reduced. Oral administration of beta-CM-7 to diabetic rats showed an increase in the level of plasma insulin, the elevated plasma glucagon level was markedly reduced by the oral administration of beta-CM-7. Oral administration of beta-CM-7 to the diabetic group of rats also showed a significant elevation in the activity of SOD and catalase. Thus, the results of the present study suggest that beta-casomorphin-7 can protect rats from hyperglycemia and free radical-mediated oxidative stress in diabetic rats.
Yin
Hong
H
Key Laboratory of Animal Physiology and Biochemistry, Nanjing Agricultural University, Nanjing 210095, People's Republic of China.
Miao
Jinfeng
J
Zhang
Yuanshu
Y
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D004723:Endorphins / Q000627:therapeutic use*; D005934:Glucagon / Q000097:blood; D006003:Glycogen / Q000378:metabolism; D006943:Hyperglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects; D010088:Oxidoreductases / Q000097:blood; D010446:Peptide Fragments / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects
D000975:Antioxidants; D001786:Blood Glucose; D004723:Endorphins; D007004:Hypoglycemic Agents; D007328:Insulin; D010446:Peptide Fragments; D008315:Malondialdehyde; D013311:Streptozocin; C041128:beta-casomorphin 7; D006003:Glycogen; D005934:Glucagon; D010088:Oxidoreductases